New peptide analgesic, μ1-opioid receptor agonist tafalgin, in multimodal pain management. First results of using in a multidisciplinary hospital
https://doi.org/10.17650/2782-3202-2024-4-1-78-84
Abstract
Therapy of chronic pain syndrome and adequate perioperative pain management during treatment of malignant neoplasms are important problems at the current stage of clinical medicine development. Currently, multimodal pain management is effectively applied through drugs of various pharmacological groups prescribed depending on pain intensity in accordance with a digital rating scale. Associated adverse events as well as impossibility of using peroral or transdermal forms in some cases, limit the use of opioid analgesics. High bioavailability and fast absorption of μ1-opioid receptor agonist tafalgin shown during preclinical studies, relatively favorable safety profile allowed to use this drug in oncological clinic.
An experience of using tafalgin in treatment of pain syndrome in patients with malignant tumors at the “Lapino” clinical hospital since 2022 is presented. The effectiveness of the drug is evaluated, and its niche in multimodal pain management is determined.
About the Authors
V. E. Gruzdev
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
11 1st Uspenskoe Shosse, Lapino, Moscow
region 143081
M. A. Anisimov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
11 1st Uspenskoe Shosse, Lapino, Moscow
region 143081
Yu. E. Ryabukhina
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
11 1st Uspenskoe Shosse, Lapino, Moscow
region 143081
A. V. Oskolkov
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies
Russian Federation
Russian Federation
11 1st Uspenskoe Shosse, Lapino, Moscow
region 143081
P. A. Zeynalova
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies; I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University)
Russian Federation
Russian Federation
11 1st Uspenskoe Shosse, Lapino, Moscow
region 143081
Bld. 2, 8 Trubetskaya St., Moscow 119991
References
1. Gruzdev V.E., Anisimov M.A. Multimodal continuous approach to pain management in oncological patients (clinic’s first experience). MD-Onco 2022;2(1):33–8. (In Russ.). DOI: 10.17650/2782-3202-2022-2-1-33-38
2. Kosorukov V.S., Abuzarova G.R., Zakharochkina E.R. et al. Tafalgin is a Russian innovative tetrapeptide pharmaceutical for subcutaneous injection: review of the results of phase I and II clinical trials. Opukholi golovy i shei = Head and Neck Tumors 2022;12(2): 89–107. (In Russ.). DOI: 10.17650/2222-1468-2022-12-2-89-107
3. Abuzarova G.R., Kosorukov V.S., Gamzeleva O.Yu. et al. The efficacy and safety of Tafalgin in patients with cancer pain. Results of an open-label comparative multicenter randomized clinical trial. Onkologiya. Zhurnal im. P.A. Gertsena = P.A. Herzen Journal of Oncology 2022;11(5):38–48. (In Russ.). DOI: 10.17116/onkolog20221105138
4. Karelov A.E., Kosorukov V.S., Kraevskaya Yu.N. et al. Effectiveness of the new peptide analgesic Tafalgin in the treatment of postoperative pain. Anesteziologiya i reanimatologiya = Russian Journal of Anesthesiology and Reanimatology 2023;(6):75–83. (In Russ.). DOI: 10.17116/anaesthesiology202306175
5. Abuzarova G.R., Sarmanaeva R.R., Alekseev G.S. et al. Orofacial pain in oncology: use of a new analgesic peptide tafalgin. Opukholi golovy i shei = Head and Neck Tumors 2023;13(3):43–50. (In Russ.). DOI: 10.17650/2222-1468-2023-13-3-43-50
6. Abuzarova G.R., Sarmanayeva R.R., Alekseeva G.S., Brazhnicova Y.V. A clinical case of the use of a new selective μ1-opioid analgesic Tafalgin in the treatment of chronic cancer pain. Sovremennaya onkologiya = Journal of Modern Oncology 2022;24(3):314–9. DOI: 10.26442/18151434.2022.3.201913
7. Konstantinova M.M., Paltuev R.M. Cancer patients with chronic pain syndrome: can we improve their quality of life? Opukholi zhenskoy reproduktivnoy systemy = Tumors of Female Reproductive System 2023;19(1):90–8. (In Russ.). DOI: 10.17650/1994-4098-2023-19-1-90-98
8. Ognerubov А.N. Therapy of chronic pain in cancer patients: Tafalgin use experience. Case report. Sovremennaya onkologiya = Journal of Modern Oncology 2023;25(1):128–32. DOI: 10.26442/18151434.2023.1.202194
9. Ryabukhina Yu.E., Zeynalova P.A., Timofeeva O.L. et al. Use of μ1-opioid receptor agonist tafalgin in integrative therapy of chronic pain syndrome in progressive multiple myeloma. Clinical observation. MD-Onco 2023;3(2):27–34. (In Russ.). DOI: 10.17650/2782-3202-2023-3-2-27-34
10. Miller R. Anesthesia. 7th edn. V. 4. Transl. from Engl. Saint Petersburg: Chelovek, 2015. P. 2978. (In Russ.).
11. Clinical recommendations. Chronic pain syndrome (CBS) in adult patients in need of palliative care. Code for ICD 10: R52.1/R52.2. 2022. (In Russ.).
12. Fallon M., Giusti R., Aielli F. et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol 2018;29(Suppl 4):iv166–iv91. DOI: 10.1093/annonc/mdy152
13. Kogonia L.M., Novikov G.A., Orlova R.V. et al. Practical recommendations for the treatment of chronic pain syndrome in adult cancer patients. Zlokachestvenniye opukholy. Prakticheskiye rekomendatsii RUSSCO = Malignant tumors. Practical recommendations of RUSSCO 2022;12(3s2):182–203. (In Russ.). DOI: 10.18027/2224-5057-2022-12-3s2-182-203
14. WHO guidelines for the pharmacological and radiotherapeutic management of cancer pain in adults and adolescents. Geneva: WHO, 2018. Available at: https://www.who.int/publications/i/item/9789241550390
15. Mao J.J., Ismaila N., Bao T. et al. Integrative medicine for pain management in oncology: Society for Integrative Oncology – ASCO guideline. J Clin Oncol 2022;40(34):3998–4024. DOI: 10.1200/JCO.22.01357
16. Paice J.A., Bohlke K., Barton D. et al. Use of opioids for adults with pain from cancer or cancer treatment: ASCO Guideline. J Clin Oncol 2023;41(4):914–30. DOI: 10.1200/JCO.22.02198
17. Ovechkin A.M., Bayalieva A.Zh., Ezhevskaya A.A. et al. Postoperative analgesia. Guidelines. Vestnik intensivnoy terapii im. A.I. Saltanova = A.I. Saltanov Bulletin of Intensive Care 2019;(4):9–33. DOI: 10.21320/1818-474X-2019-4-9-33
Review
For citations:
Gruzdev V.E., Anisimov M.A., Ryabukhina Yu.E., Oskolkov A.V., Zeynalova P.A. New peptide analgesic, μ1-opioid receptor agonist tafalgin, in multimodal pain management. First results of using in a multidisciplinary hospital. MD-Onco. 2024;4(1):78-84. (In Russ.) https://doi.org/10.17650/2782-3202-2024-4-1-78-84
Views:
523
Email this article 